Відмінності між версіями «Le illness in peripheral blood or bone marrow even when»
м |
м |
||
| Рядок 1: | Рядок 1: | ||
| − | These individuals are | + | These individuals are viewed as to have accomplished a minimal residual disease (MRD) adverse status.17-20 Various phase II trials have demonstrated that individuals attaining MRD negativity possess a signif-icantly longer survival than those that stay MRD good, and this really is true for individuals treated with standard chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) recently revealed that [http://hsepeoplejobs.com/members/dealpin58/activity/360528/ 887 upregulated and 1341 downregulated (Table 1). {In order to|To be able to] patients acquiring MRD negativity had substantially longer progression-free and general survivals, irrespectively of the therapy received.18 However, nevertheless, a few of these studies were flawed by inappropriate statistical evaluation, particularly the measurement of time-to-event outcomes from treatment initiation.27 Furthermore, there are several caveats for the use of MRD evaluation in sufferers with CLL.28 Very first, CLL remains incurable and at the least 30 of individuals who reach MRD negativity after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC eventually practical experience a disease relapse inside five years.18 Secondly, unlike the predicament in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is certainly no formal proof of a therapeutic benefit of re-treatment upon documentation of MRD positivity just after an initial MRD-negative response when compared with treatment at the time of clinical relapse. All calculations were performed making use of either SPSS, version 18.0, or R, version 3.0.1. Two-sided P values 0.05 were viewed as statistically significant. A detailed explanation of your statistical approaches is accessible in the On the web Supplement.Results Baseline characteristicsThe median age from the whole cohort was 58 years (range, 27-93 years), and the percentage of individuals older than 70 years was 22 . As outlined by D ner's hierarchical model, 17/221 (eight ) and 40/221 (18 ) individuals had 17p deletion and 11q deletion, respectively.Le disease in peripheral blood or bone marrow even when really sensitive immunophenotypic or molecular methods are employed to appear for residual disease. These sufferers are considered to possess achieved a minimal residual illness (MRD) unfavorable status.17-20 Several phase II trials have demonstrated that patients reaching MRD negativity have a signif-icantly longer survival than people who stay MRD positive, and this really is true for individuals treated with traditional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) lately revealed that individuals obtaining MRD negativity had significantly longer progression-free and general survivals, irrespectively with the therapy received.18 Unfortunately, however, some of these studies were flawed by inappropriate statistical evaluation, specifically the measurement of time-to-event outcomes from treatment initiation.27 Moreover, there are lots of caveats for the use of MRD analysis in patients with CLL.28 First, CLL remains incurable and no less than 30 of individuals who reach MRD negativity soon after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC at some point experience a illness relapse within 5 years.18 Secondly, as opposed to the scenario in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there's no formal proof of a therapeutic benefit of re-treatment upon documentation of MRD positivity after an initial MRD-negative response when compared with remedy at the time of clinical relapse. |
Версія за 05:46, 31 січня 2018
These individuals are viewed as to have accomplished a minimal residual disease (MRD) adverse status.17-20 Various phase II trials have demonstrated that individuals attaining MRD negativity possess a signif-icantly longer survival than those that stay MRD good, and this really is true for individuals treated with standard chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) recently revealed that 887 upregulated and 1341 downregulated (Table 1). {In order to|To be able to patients acquiring MRD negativity had substantially longer progression-free and general survivals, irrespectively of the therapy received.18 However, nevertheless, a few of these studies were flawed by inappropriate statistical evaluation, particularly the measurement of time-to-event outcomes from treatment initiation.27 Furthermore, there are several caveats for the use of MRD evaluation in sufferers with CLL.28 Very first, CLL remains incurable and at the least 30 of individuals who reach MRD negativity after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC eventually practical experience a disease relapse inside five years.18 Secondly, unlike the predicament in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is certainly no formal proof of a therapeutic benefit of re-treatment upon documentation of MRD positivity just after an initial MRD-negative response when compared with treatment at the time of clinical relapse. All calculations were performed making use of either SPSS, version 18.0, or R, version 3.0.1. Two-sided P values 0.05 were viewed as statistically significant. A detailed explanation of your statistical approaches is accessible in the On the web Supplement.Results Baseline characteristicsThe median age from the whole cohort was 58 years (range, 27-93 years), and the percentage of individuals older than 70 years was 22 . As outlined by D ner's hierarchical model, 17/221 (eight ) and 40/221 (18 ) individuals had 17p deletion and 11q deletion, respectively.Le disease in peripheral blood or bone marrow even when really sensitive immunophenotypic or molecular methods are employed to appear for residual disease. These sufferers are considered to possess achieved a minimal residual illness (MRD) unfavorable status.17-20 Several phase II trials have demonstrated that patients reaching MRD negativity have a signif-icantly longer survival than people who stay MRD positive, and this really is true for individuals treated with traditional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) lately revealed that individuals obtaining MRD negativity had significantly longer progression-free and general survivals, irrespectively with the therapy received.18 Unfortunately, however, some of these studies were flawed by inappropriate statistical evaluation, specifically the measurement of time-to-event outcomes from treatment initiation.27 Moreover, there are lots of caveats for the use of MRD analysis in patients with CLL.28 First, CLL remains incurable and no less than 30 of individuals who reach MRD negativity soon after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC at some point experience a illness relapse within 5 years.18 Secondly, as opposed to the scenario in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there's no formal proof of a therapeutic benefit of re-treatment upon documentation of MRD positivity after an initial MRD-negative response when compared with remedy at the time of clinical relapse.
